Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus

Autor: Murray B. Urowitz, Cynthia Aranow, Yumi Asukai, Damon L. Bass, Ian N. Bruce, Deven Chauhan, Maria Dall'Era, Richard Furie, Norma Lynn Fox, Jennifer A. Gilbride, Anne Hammer, Ellen M. Ginzler, Tania Gonzalez‐Rivera, Roger A. Levy, Joan T. Merrill, Holly Quasny, David A. Roth, William Stohl, Ronald van Vollenhoven, Daniel J. Wallace, Michelle Petri

Publikováno v: Urowitz, M B, Aranow, C, Asukai, Y, Bass, D L, Bruce, I N, Chauhan, D, Dall'Era, M, Furie, R, Fox, N L, Gilbride, J A, Hammer, A, Ginzler, E M, Gonzalez-Rivera, T, Levy, R A, Merrill, J T, Quasny, H, Roth, D A, Stohl, W, van Vollenhoven, R, Wallace, D J & Petri, M 2022, ' Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus ', Arthritis Care and Research, vol. 74, no. 11, pp. 1822-1828 . https://doi.org/10.1002/acr.24901

Organ damage is a key determinant of poor long-term prognosis and early death in patients with systemic lupus erythematosus (SLE). Prevention of damage is a key treatment goal of the 2019 update of the European Alliance of Associations for Rheumatolo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c81a899c9b46ed97a967794594c7bb5
http://www.scopus.com/inward/record.url?scp=85135523522&partnerID=8YFLogxK

Supplementary Data from Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

Autor: Stefan Sleijfer, Elisabeth G.E. de Vries, Walter J. Loos, Ferry A.L.M. Eskens, Renée Miceli, Norma Lynn Fox, Jourik A. Gietema, Corina N.A.M. Oldenhuis, Jaap Verweij, Constantijne H. Mom

Supplementary Data from Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bc8175e10fc63c1c449e22f11fd3876
https://doi.org/10.1158/1078-0432.22440649

Phase I Pharmacokinetic and Biologic Correlative Study of Mapatumumab, a Fully Human Monoclonal Antibody With Agonist Activity to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor-1

Autor: Margaret von Mehren, Anthony W. Tolcher, Amita Patnaik, Monique Hill, Neal J. Meropol, Theresa Mays, Norma Lynn Fox, Kristin Padavic, Alfred Corey, Monica M. Mita, Therese McCoy, Wendy Halpern, Roger B. Cohen

Publikováno v: Journal of Clinical Oncology. 25:1390-1396

Purpose To assess the safety, pharmacokinetics, and preliminary evidence of antitumor activity of mapatumumab (HGS-ETR1, TRM-1), a fully human agonist monoclonal antibody directed to the tumor necrosis factor–related apoptosis-inducing ligand recep

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::85b0b15083364183bb2af543b89e423c
https://doi.org/10.1200/jco.2006.08.8898

[Untitled]

Autor: Ann Hickey, Donald B. Hunninghake, Norma Lynn Fox, Jeffrey L. Probstfield, Michael L. Terrin, Jeanine M. Walenga, J.Alan Herd, Roque Pifarré, Sandra A. Forman, Byron J. Hoogwerf, Debra Hoppensteadt, Lucien Campeau

Publikováno v: Journal of Thrombosis and Thrombolysis. 11:143-149

Background: Since coronary artery bypass graft patients remain at risk of coronary artery and bypass graft occlusion after successful surgery, adjunct treatment regimens are under investigation. In a study of the patients of the multicenter Post Coro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d46455b9481d4ec7d6bfa5c5d175cbb8
https://doi.org/10.1023/a:1011276700426

Quality of life after coronary artery bypass graft: results from the POST CABG Trial

Autor: Norma Lynn, Fox, Byron J, Hoogwerf, Susan, Czajkowski, Ruth, Lindquist, Gilles, Dupuis, J Alan, Herd, Lucien, Campeau, Ann, Hickey, Franca B, Barton, Michael L, Terrin

Publikováno v: Chest. 126(2)

The POST CABG (Post Coronary Artery Bypass Graft) Trial showed that aggressive lowering of low-density lipoprotein (LDL) cholesterol levels reduced the progression of atherosclerosis in saphenous vein grafts. In the extended follow-up phase, aggressi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d8907abb5a2a075459ecb933e6593cdc
https://pubmed.ncbi.nlm.nih.gov/15302735